| |
Gain expert advice on navigating the stakeholder ecosystem—from payers and policymakers to patients and community oncologists. Download the eBook now to drive commercial success and outcomes in cancer care.
+(1).png)
|
|
Today's Big NewsJul 18, 2023 |
| By Nick Paul Taylor Novartis has dumped its secretive, high-risk, high-reward obesity candidate after emerging from a phase 2 trial with lackluster efficacy. The Swiss drugmaker disclosed the termination alongside news that it is stopping development of a phase 3 pancreatic cancer candidate “based on benefit-risk assessment.” |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Angus Liu On the heels of wrapping up a $15 billion share buyback, Novartis has unveiled another stock repurchase plan of the same size. This comes even as the company's top-selling drug, Entresto, faces patent challenges. |
By Gabrielle Masson Pfizer and Flagship Pioneering have each put down $50 million to build a new pipeline of 10 programs, with the Big Pharma offering Flagship and its bioplatform companies the chance to earn up to $700 million in biobucks for each program that makes it to market. |
By Conor Hale The two companies aim to get ahead of potentially high patient demand as advancements are made in hopefully treating the neurodegenerative condition. |
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more. 
|
|
By Fraiser Kansteiner In tandem with Taiwan’s Food and Drug Administration, GSK this week initiated a recall of two batches of its severe asthma injection Nucala after glass fragments were found in a vial of the drug. |
By Nick Paul Taylor Neurogene has struck deals to fund its pipeline of gene therapies into the second half of 2026, agreeing to merge with the floundering, Nasdaq-listed Neoleukin Therapeutics and persuading investors to pump $95 million into the combined company. |
By Andrea Park After a tumultuous few months sent Masimo’s second-quarter earnings on a downward spiral, the company is tempering expectations for the rest of the year. |
By Kevin Dunleavy With the acquisition of two commercial medicines from Travere Therapeutics, liver disease specialist Mirum Pharmaceuticals has gone from a company with one product to having a “franchise,” according to CEO Chris Peetz. Now—in addition to its potential blockbuster Livmarli—Mirum has gained bile acid treatments Cholbam and Chenodal for $210 million upfront and $235 million in potential milestones. |
By Conor Hale Abiomed has identified 27 cases where the stent-like struts on the outer edge of the TAVR implant have connected with the Impella’s spinning blades. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
